Home » Stocks » NVTA

Invitae Corporation (NVTA)

Stock Price: $40.13 USD 0.33 (0.83%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $39.90 -0.23 (-0.57%) Feb 26, 7:58 PM
Market Cap 7.65B
Revenue (ttm) 245.45M
Net Income (ttm) -444.74M
Shares Out 132.48M
EPS (ttm) -4.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $40.13
Previous Close $39.80
Change ($) 0.33
Change (%) 0.83%
Day's Open 40.11
Day's Range 37.70 - 41.07
Day's Volume 4,862,985
52-Week Range 7.41 - 61.59

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 4 days ago

The healthcare company is diving along with the market.

PRNewsWire - 4 days ago

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advan...

The Motley Fool - 5 days ago

There's nothing to be alarmed about.

24/7 Wall Street - 1 week ago

With the trading day more than halfway over, the broad markets were trading lower with the Dow down about 0.4 while the S&P 500 traded down about 0.5% and Nasdaq traded down nearly 0.9%.

Other stocks mentioned: MU, STX
Benzinga - 1 week ago

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly ow...

Other stocks mentioned: VERU, CYH, MTEM
The Motley Fool - 1 week ago

The company's revenue soared, but so did its expenses.

Zacks Investment Research - 1 week ago

Invitae (NVTA) delivered earnings and revenue surprises of -8.62% and 2.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 week ago

Shares of Invitae (NYSE:NVTA) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.63), which...

Benzinga - 1 week ago

Invitae (NYSE:NVTA) unveils its next round of earnings this Wednesday, February 17. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Zacks Investment Research - 1 week ago

Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.

The Motley Fool - 1 week ago

Two innovative small companies with scorching growth and one bargain biotech.

Other stocks mentioned: PGNY, VRTX
Zacks Investment Research - 2 weeks ago

Invitae (NVTA) closed the most recent trading day at $51.09, moving -1.64% from the previous trading session.

Zacks Investment Research - 2 weeks ago

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 weeks ago

SAN FRANCISCO, Feb. 10, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the 10th ...

Zacks Investment Research - 3 weeks ago

In the latest trading session, Invitae (NVTA) closed at $49.70, marking a -0.98% move from the previous day.

PRNewsWire - 3 weeks ago

SAN FRANCISCO, Feb. 3, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2020 fina...

The Motley Fool - 3 weeks ago

The takeaways go beyond coronavirus testing, treatments, and vaccines.

Other stocks mentioned: TDOC
Business Wire - 4 weeks ago

BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balan...

The Motley Fool - 4 weeks ago

Genetic testing companies have to appeal to several stakeholders in the healthcare system in order to make it to the next level.

Other stocks mentioned: CRSP, FLGT
Zacks Investment Research - 1 month ago

Invitae (NVTA) closed the most recent trading day at $47.69, moving -0.96% from the previous trading session.

PRNewsWire - 1 month ago

SAN FRANCISCO, Jan. 26, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 8,932,038 shares of its common stock, including...

PRNewsWire - 1 month ago

SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price ...

PRNewsWire - 1 month ago

SAN FRANCISCO, Jan. 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $400.0 million of shares of its common st...

The Motley Fool - 1 month ago

Those are some solid endorsements.

Other stocks mentioned: BMY, JNJ, NVS, RHHBY
PRNewsWire - 1 month ago

SAN FRANCISCO, Jan. 14, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the launch of a new project with Bristol Myers Squibb, Jansse...

The Motley Fool - 1 month ago

Investors appear to like the company's new collaboration with PacBio.

The Motley Fool - 1 month ago

Should investors be worried?

Other stocks mentioned: SAM, SQ
PRNewsWire - 1 month ago

SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong grow...

InvestorPlace - 1 month ago

Supporting the case for being constructive on stocks in 2021is the sheer depth of where hot stocks hail from. Last year, the technology and consumer discretionary sectors were the two largest ...

Other stocks mentioned: ATEN, CAT, CZR, DKNG, INTC, NNDM
The Motley Fool - 1 month ago

Berkshire's best days seem to be behind it, but this investing wiz could be the next Buffett.

Other stocks mentioned: ARKF, ARKG, ARKK, ARKQ, ARKW, CRSP, ROKU, SQ, TSLA
PRNewsWire - 1 month ago

SAN FRANCISCO, Dec. 29, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of I...

Seeking Alpha - 2 months ago

The rapid adoption of telemedicine and digital health during COVID-19 pandemic is remarkable, yet unsurprising. In the years preceding the health crisis we now find ourselves in, a paradigm sh...

Other stocks mentioned: IRTC, NUAN, TDOC
Seeking Alpha - 2 months ago

The cost of sequencing a human genome has been falling faster than Moore's law. The interpretation of results is another important aspect to consider to reduce costs.

PRNewsWire - 2 months ago

SAN FRANCISCO, Dec. 17, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine ...

InvestorPlace - 2 months ago

Advanced Micro Devices, Aurora Cannabis, Invitae and SunPower were our top stock trades for Wednesday. Now, let's have a look at the charts.

Other stocks mentioned: AMD, ACB, SPWR
PRNewsWire - 2 months ago

SAN FRANCISCO, Dec. 9, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast...

Forbes - 2 months ago

The shares of Invitae Corporation (NVTA) are up 1% at $54.73 at last check, approaching yesterday's record high of $57.12.

Seeking Alpha - 2 months ago

Invitae loses money today but has the potential to monopolize the germline testing market. They use volume and COGS metrics to demonstrate the plausibility of their business model, but these m...

InvestorPlace - 3 months ago

Investors love disruptive themes and innovation stocks. Some of those assets are already delivering massive gains to investors.

Other stocks mentioned: ARKF, ROKU
InvestorPlace - 3 months ago

Data stocks often fly under the radar. However, investors should keep these names in mind as they power tech innovations forward.

Other stocks mentioned: AYX, CRM, DDOG, MDB, SNOW, SPLK
The Motley Fool - 3 months ago

The medical genetics company easily topped Wall Street's top- and bottom-line estimates in the third quarter.

Seeking Alpha - 3 months ago

Invitae Corporation. (NVTA) CEO Sean George on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Invitae (NVTA) delivered earnings and revenue surprises of -3.33% and 14.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 3 months ago

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.

Zacks Investment Research - 3 months ago

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

SAN FRANCISCO, Oct. 23, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results ...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.

PRNewsWire - 4 months ago

SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherD...

Zacks Investment Research - 4 months ago

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

Other stocks mentioned: BDX, EXAS, GH, ILMN, NTRA, QDEL
The Motley Fool - 4 months ago

Which stock wins in this genetics version of David versus Goliath?

Other stocks mentioned: ILMN

About NVTA

Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and c... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 12, 2015
CEO
Dr. Sean Emerson George
Country
United States
Stock Exchange
NYSE
Ticker Symbol
NVTA
Full Company Profile

Financial Performance

In 2019, NVTA's revenue was $216.82 million, an increase of 46.80% compared to the previous year's $147.70 million. Losses were -$241.97 million, 87.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for NVTA stock is "Buy." The 12-month stock price forecast is 54.60, which is an increase of 36.06% from the latest price.

Price Target
$54.60
(36.06% upside)
Analyst Consensus: Buy